Subjects not receiving antidiabetes therapy for 12 weeks were randomized to empagliflozin 25 mg/linagliptin 5 mg ( n = 137 ) , empagliflozin 10 mg/linagliptin 5 mg ( n = 136 ) , empagliflozin 25 mg ( n = 135 ) , empagliflozin 10 mg ( n = 134 ) , or linagliptin 5 mg ( n = 135 ) for 52 weeks .